Refametinib ≥98% (by HPLC)
Synonyms:
(S)-N-(3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulphonamide
, (S)-N-(3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
, N-[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulphonamide
, BAY 86-9766
, N-[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide
Refametinib (BAY 86-9766; previously RDEA119) is a highly selective and potent orally available inhibitor of MEK 1 and MEK 2. It displays potent in vitro and in vivo antitumor activity in multiple preclinical cancer models, including melanoma, colorectal cancer, non-small cell lung cancer, epidermal carcinoma, and HCC.
Formula:
C₁₉H₂₀F₃IN₂O₅S MW: 572,34 g/mol |
MDL Number:
MFCD18633256 CAS Number: 923032-37-5 |
Learn more
About VWR
Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...